Ventricular Septal Defect (VSD) Closures | Cardiology Treatments — Cost, Top Hospitals & Success Rates | MyMedicPlus

A ventricular septal defect (VSD) is a congenital or acquired opening in the interventricular septum — the muscular wall separating the left and right ventricles of the heart. It is the most common congenital heart defect, accounting for approximately 25–30% of all congenital heart disease, with an incidence of 2–3 per 1,000 live births in isolated form. The haemodynamic consequence of a VSD is a left-to-right shunt: because left ventricular pressure exceeds right ventricular pressure, blood flows abnormally from left to right across the defect with each systole, volume-loading the pulmonary circulation, left atrium, and left ventricle. The magnitude of shunting depends on defect size and the ratio of pulmonary to systemic vascular resistance (Qp:Qs ratio).

Small VSDs with Qp:Qs ratios below 1.5:1 are haemodynamically insignificant and often close spontaneously in childhood — up to 50% of perimembranous VSDs and up to 80% of muscular VSDs close without intervention within the first 5 years of life. Large unrestricted VSDs with Qp:Qs above 2:1 cause volume overload of the left heart with left ventricular dilation, pulmonary hypertension, and eventually (if uncorrected) Eisenmenger syndrome — irreversible pulmonary vascular obstructive disease with reversal of shunting direction (right-to-left), profound cyanosis, and severely limited life expectancy.

VSD closure can be achieved by two main approaches: surgical repair using cardiopulmonary bypass and a patch to close the defect, or transcatheter device closure using a catheter-delivered occlusion device (most commonly the Amplatzer Ventricular Septal Occluder). The choice of approach depends on defect anatomy, location, size, the patient's age and weight, associated cardiac defects, and centre expertise. Perimembranous VSDs near the aortic valve require careful technique due to the proximity of the His bundle and risk of heart block. Muscular and outlet VSDs are often amenable to device closure.

VSD closure is indicated for haemodynamically significant VSDs causing left ventricular volume overload, recurrent respiratory infections (from pulmonary plethora), failure to thrive in infants, exercise intolerance, or pulmonary arterial hypertension in the absence of fixed irreversible pulmonary vascular disease. The standard indication is a VSD with Qp:Qs above 1.5–2.0:1 with evidence of left ventricular volume overload on echocardiography (LV enlargement) or clinical symptoms. VSDs associated with aortic valve prolapse (causing progressive aortic regurgitation) are closed regardless of shunt size to prevent worsening valve incompetence.

Post-myocardial infarction VSD — a rare but life-threatening complication of acute MI occurring in 0.1–0.3% of STEMI cases — requires urgent closure, typically via surgical repair (or transcatheter closure as a bridge) in the context of cardiogenic shock. VSDs occurring post-cardiac surgery (residual or patch dehiscence) are managed similarly. Eisenmenger syndrome represents a contraindication to VSD closure — the elevated pulmonary vascular resistance is irreversible and closure would precipitate acute right heart failure. Reversibility of pulmonary hypertension must be assessed with vasodilator testing (oxygen, iloprost, nitric oxide) and sometimes lung biopsy before closure in borderline cases.

Infants and children with large VSDs causing failure to thrive, recurrent lower respiratory tract infections, or pulmonary hypertension are typically operated on early (within the first 6–12 months of life) to prevent irreversible pulmonary vascular disease. Adults with previously undetected or partially closed VSDs presenting with symptoms or LV dilation should undergo closure if the defect remains haemodynamically significant. Transcatheter device closure is most suitable for muscular and perimembranous VSDs in patients weighing at least 5–8 kg (depending on the device), with adequate septal rim around the defect to anchor the device safely, without significant aortic valve prolapse, and at centres with appropriate interventional expertise.

The evaluation for VSD closure involves transthoracic and transoesophageal echocardiography (defining defect location, size, morphology, and associated lesions), cardiac catheterisation (measuring Qp:Qs, right heart pressures, and pulmonary vascular resistance in patients with suspected pulmonary hypertension), and, in adults, coronary angiography to identify concomitant CAD. Closure is contraindicated in established Eisenmenger syndrome (pulmonary vascular resistance indexed above 8 Wood units/m² unresponsive to vasodilators) and in patients with active endocarditis (requiring 6 months of antibiotic therapy before elective closure).

Surgical VSD repair remains the gold standard for most defects, particularly perimembranous VSDs, large muscular VSDs, inlet VSDs, and VSDs with associated lesions (aortic regurgitation, LVOT obstruction). The procedure requires cardiopulmonary bypass, cardioplegic cardiac arrest, and direct suture closure or patch placement (pericardial or Dacron patch) via right atriotomy or right ventriculotomy. Results are excellent — closure success above 95%, with very low mortality (below 1%) in non-complex cases at experienced centres. The conduction system (AV node and His bundle) lies in close proximity to perimembranous VSDs, and inadvertent damage can cause complete heart block requiring pacemaker implantation in approximately 1–2% of cases.

Transcatheter VSD closure uses a catheter-based approach under general anaesthesia and fluoroscopic or transoesophageal echocardiographic guidance. A delivery sheath is advanced from the femoral vein, across the VSD via a wire loop established between femoral artery and vein, and a self-expanding nitinol mesh device (Amplatzer Muscular VSD Occluder, Amplatzer Membranous VSD Occluder, or the newer ADO II Extra Small for small perimembranous VSDs) is deployed to straddle the defect. Complete closure rates are approximately 85–95% at 12 months for muscular VSDs and 70–85% for perimembranous VSDs, with residual small shunts frequently being clinically insignificant. The risk of complete heart block with perimembranous device closure remains a concern (0.8–3%), leading some centres to prefer a hybrid approach (perventricular closure under direct vision without bypass).

Successful VSD closure normalises the left-to-right shunt, resolves volume overload of the pulmonary circulation and left heart, and allows reverse remodelling of the left ventricle — LV dilation regresses over months following closure. Symptoms of heart failure, recurrent respiratory infections, and exercise intolerance resolve in the great majority of patients. In children, growth and developmental milestones normalise after successful repair of large VSDs. The risk of infective endocarditis, which is elevated in patients with unrepaired VSDs, is significantly reduced after successful closure (though a 6-month course of antibiotic prophylaxis for dental procedures is recommended until complete closure is confirmed).

For transcatheter closure, the major advantage over surgery is avoidance of cardiopulmonary bypass and sternotomy, resulting in a shorter hospital stay (typically 1–2 days versus 5–7 days), faster recovery, absence of a sternal scar, and lower procedural morbidity. For post-MI VSDs, survival after closure is substantially higher than medical management alone, with 30-day mortality of approximately 40–45% even with intervention, reflecting the critical haemodynamic compromise of this population. Pulmonary hypertension attributable to the shunt (rather than established pulmonary vascular disease) resolves or significantly improves following successful closure.

Surgical VSD repair risks include the standard open-heart surgery risks: stroke (below 1%), bleeding requiring transfusion, deep sternal wound infection (0.5–2%), prolonged mechanical ventilation, and in-hospital mortality (below 1% in isolated VSD repair at experienced centres in children, up to 3–5% with complex associated lesions or in critically ill patients). Complete heart block requiring pacemaker implantation occurs in 1–2% of perimembranous VSD repairs — higher than the general pacemaker implantation rate in other cardiac surgeries. Residual VSD (small shunt through the patch or around the suture line) occurs in up to 5–10% but most are clinically trivial.

Transcatheter VSD device closure risks include device embolisation (0.5–3%), arrhythmias during catheter manipulation (transient usually), haemolysis from high-velocity shunting around an incompletely seated device (typically resolves with complete device endothelialisation at 3 months), complete heart block (0.8–3% for perimembranous VSDs — sometimes with delayed onset weeks to months after implantation), aortic regurgitation from device impingement on the aortic valve leaflets, and tricuspid valve regurgitation. The risk of late complete heart block after device implantation necessitates prolonged ECG monitoring with ambulatory Holter monitoring for 12 months post-procedure.

After surgical VSD repair, patients are typically in intensive care for 24–48 hours before transfer to a ward, with total hospital stay of 5–7 days in uncomplicated cases. A sternal wound check is performed at 1 week. Echocardiography at 6 weeks post-surgery confirms complete defect closure and LV remodelling. Annual cardiology follow-up is recommended for at least 5 years, monitoring for residual shunts, pulmonary hypertension regression, LV function, and the integrity of the repair. Patients who had pulmonary hypertension before repair require particularly careful follow-up to document pulmonary pressure normalisation.

After transcatheter device closure, patients are discharged within 24–48 hours. Antiplatelet therapy (aspirin 5 mg/kg/day for 6 months) reduces the risk of device thrombosis during the endothelialisation process. Echocardiography at 1, 6, and 12 months documents device position, residual shunting, and LV remodelling. ECG and Holter monitoring at regular intervals for 12 months screens for late-onset complete heart block after perimembranous device closure. Dental and surgical procedures during the first 6 months post-closure require antibiotic prophylaxis per endocarditis guidelines.

In the United States, surgical VSD repair costs $30,000–$80,000 including hospital stay, depending on hospital type, patient complexity, and insurance. Transcatheter VSD closure costs $25,000–$55,000 including device, catheterisation laboratory use, and hospitalisation. These costs represent a substantial barrier for uninsured or internationally uninsured patients.

India is a leading destination for VSD closure as medical tourism, with outstanding expertise in paediatric and congenital cardiac surgery and interventional cardiology. Surgical VSD repair at JCI-accredited centres such as Narayana Hrudayalaya, Apollo Hospitals, and Fortis cost $4,000–$8,000, including all surgical and anaesthetic fees, 5–7 day hospital stay, and follow-up echocardiography. Transcatheter device closure is available for $3,500–$7,000, with device costs (Amplatzer occluders) significantly lower due to different pricing structures for emerging markets. Thailand and Singapore offer congenital heart surgery at $8,000–$20,000, representing savings of 60–75% versus US prices. The high volume of congenital heart surgery at dedicated Indian centres means surgeons have exceptional experience with even complex cases.

Medical management with diuretics, afterload reduction, and digoxin may be used short-term to improve haemodynamic status in infants with large VSDs and heart failure before definitive surgical repair, but it is not a definitive treatment and does not prevent the development of pulmonary vascular disease if the defect is not closed. Pulmonary artery banding — surgical narrowing of the main pulmonary artery to reduce pulmonary blood flow — was historically used as a palliative procedure in complex VSD cases to delay definitive repair, but is now rarely used given the excellent results of primary complete repair even in small infants.

Watchful waiting with serial echocardiography is appropriate for small VSDs without haemodynamic significance (Qp:Qs below 1.5:1, no LV dilation), which may close spontaneously. Infective endocarditis prophylaxis guidelines (antibiotic cover for dental procedures) apply to all unrepaired VSDs during the surveillance period. Genetic counselling is recommended for parents of children with VSDs regarding the 3–5% recurrence risk in subsequent pregnancies.